Roivant Sciences (ROIV) Payables (2021 - 2026)

Roivant Sciences has reported Payables for 6 years, with the latest figure at $18.0 million in Q1 2026.

• For the quarter ending Q1 2026, Payables fell 24.01% year-over-year to $18.0 million; the trailing twelve-month figure through Mar 2026 stood at $18.0 million (down 24.01% YoY), and the FY2026 full-year result was $18.0 million, down 24.01% from the prior year.
• Payables for Q1 2026 stood at $18.0 million, up from $13.3 million in the prior quarter.
• The five-year high for Payables was $194.6 million in Q2 2022, with the low at $11.5 million in Q2 2025.
• Historically, Payables has averaged $38.7 million across 5 years, with a median of $27.7 million in 2024.
• Annual changes were most pronounced in 2022 — Payables jumped 1196.18% — and 2023, when it slumped 74.29%.
• Roivant Sciences' Payables stood at $48.0 million in 2022, then fell by 26.61% to $35.2 million in 2023, then tumbled by 32.69% to $23.7 million in 2024, then sank by 43.94% to $13.3 million in 2025, then surged by 35.41% to $18.0 million in 2026.
• The last three Payables figures came in at $18.0 million (Q1 2026), $13.3 million (Q4 2025), and $15.1 million (Q3 2025), per Business Quant data.